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In this issue of Cancer Cell, Li and colleagues demonstrate that the hematopoietic transcription factor Aiolos
(named after theWindGod of Greekmythology) confers anoikis resistance in lung tumor cells through repres-
sion of cell adhesion-related genes including the mechanosensor p66Shc.Co-opting programming factors ordinarily
found only in alternative cell lineages for
the purpose of evading anoikis has been
reported in other settings, for example,
activation of the neuronal trkB and NGF
genes in breast cancer. The paper by Li
et al. (2014) in this issue of Cancer
Cell provides provocative evidence that
lung cancer cells utilize a hemato-
poietic transcription factor, Aiolos, to
drive both anoikis resistance and
anchorage independence.
Aiolos/Ikaros family zinc finger 3
(IKZF3) is a member of the Ikaros family
of lymphocyte maturation-driving tran-
scription factors (originally described by
the Georgopoulis laboratory), which
also includes Eos, Helios, and Pegasus.
Aiolos is expressed late in B- and T cell
maturation, when cells become inde-
pendent of attachment to the bone
microenvironment and prepare to circu-
late (John and Ward, 2011). Initial studies
to define the role of these transcription
factors in cancer progression naturally
focused upon hematopoietic malig-
nancies. Most studies have examined
Ikaros, the founding member of the
family with tumor suppressor function
that, when mutated, generates aberrant
anoikis-resistant precursors to B cell
acute lymphoblastic leukemia (Joshi
et al., 2014). However, there are sce-
narios where Ikaros family members
have a protumorigenic function in
hematopoietic cancers. For example,
Aiolos expression is elevated in chronic
lymphocytic leukemia and is proposed
to promote cell survival by regulation of
Bcl2 family proteins (Billot et al., 2011).
Aberrant expression of Ikaros family
members in solid tumors, including lung
and ovarian cancers has been reported,
but a unifying concept of their function
in solid tumors has not emerged. Li
et al. (2014) significantly advance thesestudies by providing unique insight into
the mechanisms through which Aiolos
subverts normal epithelial cell function
to drive phenotypes associated with
malignant disease. Aiolos and its relatives
repress transcription through chromatin
remodeling factors including the NuRD
and CtBP complexes (Mandel and Gros-
schedl, 2010). Interestingly, both of these
complexes have been implicated widely
in tumorigenesis, the latter being a critical
factor for epithelial-mesenchymal transi-
tion (EMT) and accompanying acquisition
of resistance to anoikis (Grooteclaes
et al., 2003), and, in this connection,
Ikaros is implicated in ovarian cancer
cells in the control of expression of
several genes associated with EMT. Li
et al. (2014) demonstrate that Aiolos
represses a number of integrin and tight
junction genes, thus inhibiting both
cell-matrix and cell-cell adhesion. The
ensuing breakdown of cell polarity may
well drive anoikis resistance through
Wnt, TGF-b, and Hippo pathways acting
in concert, as reviewed recently (Frisch
et al., 2013). In addition, Aiolos also spe-
cifically repressed expression of the p66
isoform of Shc, which may have a pro-
found effect upon anoikis via multiple
mechanisms.
The p66Shc repression is of unique
importance, because this protein, an
alternative splice variant of the SHC1
gene (that also encodes p52Shc, a mito-
genic tyrosine kinase receptor adaptor
protein), is critical for anoikis sensitivity
in diverse normal and tumor cell types
(Ma et al., 2007). The Terada lab reported
previously, using ectopic expression and
knockdown approaches, that p66Shc is
a mechanosensory component that
translates changes in cell-matrix ten-
sion occurring in matrix detachment or
reattachment into cell death or survival
responses (Ma et al., 2007). RhoACancer Celwas proposed to become hyperactive
in p66Shc-expressing detached cells,
generating outward force that is unop-
posed by matrix and engaging an anoikis
triggering mechanism (Ma et al., 2007).
Li et al. (2014) now demonstrate that
p66Shc is a direct target of repression
by Aiolos, which interacts with enhancer
elements and interferes with enhancer-
promoter interactions (shown by chro-
matin conformation capture), estab-
lishing repressive histone modifications
(Figure 1). Identification of the enhancer
protein(s) driving p66Shc expression
may shed additional light upon both this
repression mechanism and the regulation
of this gene more broadly. Importantly,
the re-expression of p66Shc in Aiolos-
expressing cells restored anoikis sensi-
tivity and anchorage dependence,
demonstrating the functional significance
of Aiolos-dependent p66Shc repression.
Alternative mechanisms involving the
loss of cell adhesion molecules and re-
sulting depolarization were not explored,
and the possibility that these adhesion
molecules act in part through regulating
p66Shc has not been excluded. This
mechanism is certainly plausible given
that p66Shc upregulation by cell conflu-
ence has been noted (Ma et al., 2007).
Examination of human lung tumor
samples demonstrated the significance
of Aiolos and p66Shc in tumor biology
robustly. Expression of Aiolos occurred
commonly in small cell lung cancer and,
to a lesser extent, non-small cell lung
cancer. Aiolos expression correlated
with poor prognosis and inversely corre-
lated with p66Shc expression.
Several mechanisms for apoptosis
induction and tumor suppression by
p66Shc have been proposed. One is a
profound inhibition of Ras activation,
thus activating Rho and contributing
to the ‘‘(un)opposed tension’’ modell 25, May 12, 2014 ª2014 Elsevier Inc. 551
Figure 1. Proposed Mechanism for Anoikis Resistance in Lung Cancer Cells via the Overexpression of Aiolos
In normal epithelial cells, detachment engages a p66Shc-mediated response to the loss of cell tension that triggers anoikis (upper panel). With Aiolos expression
in lung cancer cells, this pathway is obviated due to the repression of p66Shc as well as other cell adhesion related genes.
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Another is the generation of mitochondrial
reactive oxygen species (ROS) through
electron transport between p66Shc and
cytochrome c, triggering the apoptotic
mitochondrial permeability transition,
perhaps by peroxidation of cardiolipin
(Giorgio et al., 2005). Additionally,
p66Shc represses the expression of the
transcription factor Nrf, thereby indirectly
downregulating antioxidant genes, in-
creasing ROS levels.
Consistent with its pro-oxidant activity,
p66Shc is an anti-longevity gene inmouse
models and was also shown to exacer-
bate insulin resistance and glucose intol-
erance (Soliman et al., 2014). Deficiency
of p66Shc contributes to the increased
carbon flux through the glycolytic
pathway as well as the pentose phos-552 Cancer Cell 25, May 12, 2014 ª2014 Elsphate and hexosamine biosynthetic path-
ways (Soliman et al., 2014). These effects
were mediated by p66Shc’s apparent
interference with the stimulation of
mTOR by growth factors. In light of the
importance of these metabolic pathways
in anoikis, this may provide an additional
mechanism by which Aiolos regulates
anoikis through p66Shc.
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